United States: Fraud On The FDA Doesn't Fly Under The FCA Either

Last Updated: December 29 2016
Article by James Beck

Ever since Buckman Co. v. Plaintiffs' Legal Committee, 531 U.S. 341 (2001), held that state-law claims alleging fraud on the FDA are preempted, plaintiffs have been attempting to find some other way of bringing claims that attribute FDA actions to a defendant's false pretenses. Since preemption is based on the Supremacy Clause, and the constitutional relationship between the federal and state legal systems, the doctrine doesn't apply where recovery is sought under a federal statute. Since the False Claims Act ("FCA") is a federal statute, sporadic attempts have been made to bring private fraud-on-the FDA-claims under that statute. Bexis, who invented what became the Buckman fraud-on-the-FDA/implied-preemption defense in the Bone Screw litigation, even worked on an amicus brief in one such case, United States ex rel. Gilligan v. Medtronic, Inc., 403 F.3d 386 (6th Cir. 2005), that was ultimately decided (favorably to the defense) on other grounds.

A little less than a year ago we reported on an excellent FCA result in United States ex rel. D'Agostino v. EV3, Inc., 153 F. Supp.3d 519 (D. Mass. 2015). Ever since we've been holding our breath, because the First Circuit has been known for pro-plaintiff rulings in cases against our drug and medical device clients. Indeed, the First Circuit once led our list the worst drug/medical device cases of the year for two years running – in 2012 and 2013. Whether something's changed since then in the First Circuit, we can't say. But we can report that the district court's dismissal of fraud-on-the-FDA-based FCA claims in D'Agostino has just been affirmed with an excellently reasoned decision. See D'Agostino v. EV3, Inc., ___ F.3d ___, 2016 WL 7422943 (1st Cir. Dec. 23, 2016).

The facts in D'Agostino were thoroughly explained in our prior post. Briefly, the relator (a fired sales rep) alleged that the defendants pulled fast ones on the FDA with respect to the approvals/supplemental approvals of two medical devices, one called "Onyx" and the other "Axium" (these defendants evidently like "x" as much as did the former Standard Oil of New Jersey). The relator-plaintiff claimed that the defendants: (1) sought approval of Onyx for a narrow indication, but intended to promote it more broadly off-label (exactly the claim in Buckman); (2) failed to live up to promises made to the FDA concerning extensive surgeon training in using Onyx (also a form of fraud on the FDA); (3) concealed the failure of Onyx's active ingredient in a different device (ditto); and (4) failed to recall earlier versions of Axium after obtaining FDA approval (not fraud on the FDA, but a theory that could dangerously penalize innovation). See D'Agostino, 2016 WL 7422943, at ??? (for some reason WL has omitted star paging, so we'll also cite to the slip opinion), slip op. at 4-8. Critically, although the FDA was informed of all of these claims, the Agency never instituted any enforcement action, nor did the government elect to join the D'Agostino FCA action. Id. at 9, 15. As discussed in the prior post, the district court dismissed all of these claims with prejudice as futile.

The First Circuit affirmed in a muscular opinion.

In the first place, fraud-on-the-FDA claims don't fit well into the FCA because the allegedly defrauded entity (the FDA) doesn't ever actually make claims or seek reimbursement of medical costs. "The FDA, however, made none of the payments at issue in this lawsuit. Rather, CMS made the payments by reimbursing physicians . . . and hospitals." Id. at 12. Because of this disconnect, the relator had to proceed under the "implied certification" theory recently allowed by the United States Supreme Court in Universal Health Services, Inc. v. United States, 136 S. Ct. 1989 (2016) (discussed here). However, the FCA's materiality standard for such claims is "demanding." D'Agostino, slip op. at 14 (quoting UHS, 136 S. Ct. at 2003).

That the defendants' misrepresentations supposedly "could have" influenced FDA approval wasn't enough. "[C]ould have . . . falls short of pleading a causal link between the representations made to the FDA and the payments made by" other government entities. Id. at 13.

If the representations did not actually cause the FDA to grant approval it otherwise would not have granted, [the government] would still have paid the claims. In this respect, [relator's] fraudulent inducement theory is like a kick shot in billiards where the cue ball "could have" but did not in fact bounce off the rail, much less hit the targeted ball.

Id. (emphasis original). Although this suit had been pending since 2010, the government continued to pay the claims at issue, which "casts serious doubt on the materiality of the fraudulent representations that [relator] alleges." Id. at 14.

Beyond materiality, the fraud-on-the-FDA allegations failed for lack of causation, and here's where things really get interesting from our point of view. If the FDA would have taken the actions it did regardless of the purported misrepresentations, there can't be causation. Id. at 15. Here, the FDA's lack of enforcement action was critical:

In the six years since [relator] surfaced the alleged fraud, the FDA has apparently demanded neither recall nor relabeling of Onyx − this notwithstanding the agency's [list of enforcement options]. The FDA's failure actually to withdraw its approval of Onyx in the face of [relator's] allegations precludes [relator] from resting his claims on a contention that the FDA's approval was fraudulently obtained.

* * * *

[C]ausation is an element of the fraudulent inducement claims [relator] alleges and . . . the absence of official action by the FDA establishing such causation leaves a fatal gap. . . . [T]he FDA approved Onyx, and has never withdrawn that approval. [Relator] therefore cannot establish a causal link between the alleged fraudulent representations made to the FDA and the payment of claims for reimbursement by the government.

Id. at 15-16, 18-19 (emphasis added).

Under this rationale, fraud on the FDA as a basis for an FCA action is effectively dead. Without FDA enforcement action, causation fails as a matter of law. Further, even if the FDA initiated enforcement action, then that administrative proceeding – not the FCA – is the proper forum to examine allegations of fraud on the FDA. Claims where a relator reports fraud to the FDA and the government "first file[s] an FCA action itself" are "likely rare" and "do[] not warrant eliminating causation as an element of the claim." Id. at 18-19. The availability of an fraud-on-the-FDA-based FCA claim in this "rare" situation, where privately supplied information induces the a successful FDA enforcement action for fraud, are indeed so "rare" that we can't think of any. In all the fraud-on-the-FDA claims we've encountered, either (as in D'Agostino) the FDA shrugged them off as meritless, or else information that the Agency itself uncovered led to an enforcement action commenced directly by the government.

The policies the First Circuit invoked in D'Agostino are as powerful as its result. Fraud-on-the-FDA claims seek to second guess FDA product approvals, and thus should not be pursued in privately-initiated litigation:

To rule otherwise would be to turn the FCA into a tool with which a jury of six people could retroactively eliminate the value of FDA approval and effectively require that a product largely be withdrawn from the market even when the FDA itself sees no reason to do so. The FCA exists to protect the government from paying fraudulent claims, not to second-guess agencies' judgments about whether to rescind regulatory rulings.

Id. at 16 (emphasis added). A private litigant should not be allowed to shout "no" where the FDA has, and continues to, say "yes."

Furthermore, D'Agostino recognized the inescapable practical problems of all private fraud-on-the-FDA claims, whether brought under federal or state pretenses – these are the same reasons that the Supreme Court gave for preemption in Buckman:

The collateral effects of allowing juries in qui tam actions to find causation by determining the judgment of the FDA when the FDA itself has not spoken are akin to those practical effects that counsel in favor of not allowing state-law fraud-on-the-FDA claims. See Buckman Co. v. Plaintiffs' Legal Committee, 531 U.S. 341, 349-51 (2001). If jurors in a single qui tam case could determine precisely what representations were essential to approval, which experts to believe, and how the FDA interpreted submissions made to it, some potential applicants who would otherwise seek approval for new products might be deterred, others might swamp the FDA with more data than it wants, and the "FDA's responsibility to police fraud consistently with the Administration's judgment and objectives" might be undercut. Id. at 350.

D'Agostino, slip op. at 16-17 (citing and quoting Buckman). "These and similar questions all support our position that the absence of some official agency action confirming its position and judgment in accordance with the law renders [relator's] fraud-on-the-FDA theory futile." Id. at 17. Like the court's prior reasoning, these practical policy reasons are rock solid. A fraud-on-the-FDA claim cannot exist without a jury being told it can ignore as supposedly "fraudulent," whatever in-force FDA decision that a private plaintiff claims was fraudulently obtained.

The other claims also failed. The purported fraud-on-the-FDA by failure-to-train claim completely failed to identify any government-paid claims that met this factual description. Id. at 22 (relator "failure to identify any specific false claim"). Nor had the relator established falsity, since the FDA-approved labeling for the device "contains no requirement that the physician must obtain the training from" defendants, and surgeons could well have been trained elsewhere. Id. at 22-23. Where have we seen that before? More fundamentally:

[T]he assumption that physicians submitted claims for reimbursement merely because many of their patients in general were insured under government programs is faulty.

Id. at 23. The manufacturing defect claim failed because the complaint "neither alleges any specific false claims" nor that false claims of that sort "were actually submitted." Id. at 25. Finally, the proposition that an improved design necessarily rendered all previously sold versions of the product "defective" was simply wrong:

[W]e agree with the district court that a product (much less an FDA-approved medical device) cannot be called defective . . . merely because new versions of the product contain design improvements. Indeed, by that standard, most every car sold to the government would be per se defective.

Id. at 26 (citation omitted).

Private plaintiffs do not have the standing to pursue, nor do individual juries have the institutional competence to decide, whether the FDA would have would have reached a different outcome had it received a different set of information than it actually evaluated. The FDA decides what drugs and medical devices should be sold in this country, not private claimants and their lawyers self-interestedly chasing big dollars. Not only was D'Agostino correctly decided, but it was decided with uncommonly powerful reasoning. Good riddance to private litigation of fraud-on-the-FDA claims of all sorts.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
James Beck
Similar Articles
Relevancy Powered by MondaqAI
Proskauer Rose LLP
Troutman Sanders LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Proskauer Rose LLP
Troutman Sanders LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions